- Home
- RPAY vs XFOR Comparison
RPAY vs XFOR Comparison
Compare RPAY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | XFOR |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 323.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RPAY | XFOR |
|---|---|---|
| Price | $3.03 | $3.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $6.81 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 958.3K | 385.3K |
| Earning Date | 02-27-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,947,000.00 | $33,979,000.00 |
| Revenue This Year | $0.22 | $1,266.01 |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $2.80 | $1.35 |
| 52 Week High | $7.57 | $16.29 |
Technical Indicators
Market Signals| Indicator | RPAY | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 31.03 | 39.80 |
| Support Level | $3.30 | $3.14 |
| Resistance Level | $3.40 | $3.78 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 29.49 | 31.79 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.